Hims & Hers Health Sued Over Billing and Privacy Allegations

Hims & Hers Health: FTC, Utah, and California Sue Hims & Hers Over Deceptive Billing and Privacy Practices

Today, the FTC, as well as regulators in California and Utah, filed a lawsuit against the telehealth provider Hims & Hers Health (HIMS), alleging that the company enrolled consumers in prescription subscriptions without their consent, obstructed cancellations, and shared sensitive health data with advertising platforms despite promising privacy. The FTC’s investigation into the company was […]

Pave: Compensation Benchmarking Service Provides Customers Access to Sensitive Non-Public Salary Data, Raising Questions About Potential Collusive Effect

Pave, a compensation benchmarking service, gives over 9,000 companies access to sensitive non- public salary and bonus data, a Capitol Forum investigation found. The platform’s features, including...

Jul 30, 2026 Read Now >

FDA’s Forthcoming Proposal Could Make Direct-to-Consumer Pharma Ads Prohibitively Long and Expensive to Run; Some Scenarios Could Make Some Current Ads Over Ten Minutes Long

An anticipated proposal from the Food and Drug Administration (FDA) could make direct-to- consumer (DTC) pharmaceutical ads so lengthy as to be cost-prohibitive, according to The Capitol Forum’s...

Jul 30, 2026 Read Now >

Health Care Weekly: FDA Compounding Advisory Committee Votes Favorably on Six Peptides; Updates on CMS’ Implementation of SDP, Provider Tax Law; Judge Dismisses NSA Case Against HaloMD in GA; CVS Accused of 340B Spread Pricing; OpenAI Faces Unlicensed Practice of Medicine Suit; FDA 483s

The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week...

Jul 29, 2026 Read Now >

Hims & Hers Health: FTC, Utah, and California Sue Hims & Hers Over Deceptive Billing and Privacy Practices

RELATED ARTICLES | Corporate investigations

Pave: Compensation Benchmarking Service Provides Customers Access to Sensitive Non-Public Salary Data, Raising Questions About Potential Collusive Effect

FDA’s Forthcoming Proposal Could Make Direct-to-Consumer Pharma Ads Prohibitively Long and Expensive to Run; Some Scenarios Could Make Some Current Ads Over Ten Minutes Long

Health Care Weekly: FDA Compounding Advisory Committee Votes Favorably on Six Peptides; Updates on CMS’ Implementation of SDP, Provider Tax Law; Judge Dismisses NSA Case Against HaloMD in GA; CVS Accused of 340B Spread Pricing; OpenAI Faces Unlicensed Practice of Medicine Suit; FDA 483s

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.